JP2012505837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505837A5 JP2012505837A5 JP2011531312A JP2011531312A JP2012505837A5 JP 2012505837 A5 JP2012505837 A5 JP 2012505837A5 JP 2011531312 A JP2011531312 A JP 2011531312A JP 2011531312 A JP2011531312 A JP 2011531312A JP 2012505837 A5 JP2012505837 A5 JP 2012505837A5
- Authority
- JP
- Japan
- Prior art keywords
- annexin
- composition
- effective
- amount
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000672 Annexin A5 Proteins 0.000 claims description 68
- 102000004121 Annexin A5 Human genes 0.000 claims description 62
- 239000000203 mixture Substances 0.000 claims description 28
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 230000000770 proinflammatory effect Effects 0.000 claims description 16
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
- 206010040047 Sepsis Diseases 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
- 230000004768 organ dysfunction Effects 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 6
- 210000002216 heart Anatomy 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 241000282472 Canis lupus familiaris Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 241000700159 Rattus Species 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 claims description 3
- 241000282887 Suidae Species 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10639008P | 2008-10-17 | 2008-10-17 | |
| US61/106,390 | 2008-10-17 | ||
| PCT/CA2009/001469 WO2010043045A1 (en) | 2008-10-17 | 2009-10-16 | Annexin and its use to treat inflammatory disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505837A JP2012505837A (ja) | 2012-03-08 |
| JP2012505837A5 true JP2012505837A5 (enExample) | 2012-12-06 |
| JP5590621B2 JP5590621B2 (ja) | 2014-09-17 |
Family
ID=42106169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531312A Active JP5590621B2 (ja) | 2008-10-17 | 2009-10-16 | 炎症性障害の処置を処置するためのアネキシンおよびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9192649B2 (enExample) |
| EP (1) | EP2349321B1 (enExample) |
| JP (1) | JP5590621B2 (enExample) |
| CN (1) | CN102256617B (enExample) |
| CA (1) | CA2740557C (enExample) |
| WO (1) | WO2010043045A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2740557C (en) | 2008-10-17 | 2020-04-14 | London Health Sciences Centre Research Inc. | Annexin and its use to treat inflammatory disorders |
| WO2010069605A2 (en) | 2008-12-19 | 2010-06-24 | Medirista Biotechnologies Ab | Oxidized cardiolipin as a novel pro-inflammatory factor |
| WO2011160845A2 (en) | 2010-06-24 | 2011-12-29 | Medirista Biotechnologies Ab | Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment |
| CN102690345B (zh) * | 2011-03-24 | 2014-03-19 | 江苏靶标生物医药研究所有限公司 | 人膜联蛋白v变体及其表达、制备和应用 |
| HUE042929T2 (hu) * | 2011-06-15 | 2019-07-29 | Resother Pharma Aps | Gyulladáscsökkentõ gyógyszerészeti termékek |
| IN2014DN07022A (enExample) * | 2012-02-21 | 2015-04-10 | Inst Nat Sante Rech Med | |
| JP2015513535A (ja) | 2012-02-21 | 2015-05-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ウイルス侵入補助因子としてのｔｉｍレセプター |
| WO2014077575A1 (ko) * | 2012-11-13 | 2014-05-22 | 다인바이오 주식회사 | 덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물 |
| GB2542391A (en) * | 2015-09-17 | 2017-03-22 | Annexin Pharmaceuticals Ab | Process of manufacture |
| GB201702144D0 (en) * | 2017-02-09 | 2017-03-29 | Annexin Pharmaceuticals Ab | Therapeutic compositions |
| WO2019238550A1 (en) * | 2018-06-12 | 2019-12-19 | Universiteit Maastricht | Method for the treatment of hypoxic-ischemic encephalopathy in newborns |
| CN109529017B (zh) * | 2018-12-25 | 2022-06-14 | 江苏靶标生物医药研究所有限公司 | 一种膜联蛋白v的应用 |
| US11357823B2 (en) * | 2019-08-30 | 2022-06-14 | Suzhou Yabao Pharmaceutical R&D Co., Ltd | Method for treating cerebral stroke |
| US20220193192A1 (en) * | 2019-08-30 | 2022-06-23 | Suzhou Yabao Pharmaceutical R&D Co Ltd | Methods of treating a traumatic brain injury |
| CN112057623A (zh) * | 2020-06-03 | 2020-12-11 | 江苏靶标生物医药研究所有限公司 | 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用 |
| WO2022073134A1 (en) * | 2020-10-09 | 2022-04-14 | London Health Sciences Centre Research Inc. | Annexin a5 compositions and methods |
| CN112618696B (zh) * | 2020-12-14 | 2023-05-05 | 南京大学 | Annexin A5在制备治疗胆汁淤积药物中的应用 |
| CN115245559A (zh) * | 2021-04-25 | 2022-10-28 | 上海萨美细胞技术有限公司 | 一种用于治疗肺损伤的药物 |
| CN117186239A (zh) * | 2022-01-30 | 2023-12-08 | 南京瑞初医药有限公司 | 融合蛋白及其应用 |
| CN118001375A (zh) * | 2023-04-12 | 2024-05-10 | 上海萨美细胞技术有限公司 | 一种用于难愈性创面修复的药物 |
| CN119097689A (zh) * | 2023-06-08 | 2024-12-10 | 上海萨美细胞技术有限公司 | 一种用于治疗卵巢功能不全的药物 |
| CN118001372A (zh) * | 2023-07-04 | 2024-05-10 | 上海萨美细胞技术有限公司 | 膜联蛋白在抗衰老中的用途 |
| WO2025086968A1 (zh) * | 2023-10-25 | 2025-05-01 | 上海萨美细胞技术有限公司 | 一种用于治疗肺纤维化的药物 |
| WO2025129329A1 (en) * | 2023-12-23 | 2025-06-26 | London Health Sciences Centre Research Inc. | Methods for treatment of sepsis |
| CN118203650B (zh) * | 2024-01-26 | 2025-04-29 | 上海萨丽斐生物科技有限公司 | 一种用于治疗色素沉着的药物 |
| CN118846001B (zh) * | 2024-07-09 | 2025-09-02 | 上海萨丽斐生物科技有限公司 | 一种具有保湿、修护、紧致、抗皱功效的组合物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0339285A3 (en) | 1988-03-31 | 1989-11-29 | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) | Recombinant endonexin ii |
| US5229367A (en) | 1991-01-21 | 1993-07-20 | Sclavo S.P.A. | Antiinflammatory peptide derived from human lipocortin V |
| CA2185535C (en) | 1994-04-11 | 2000-10-24 | Christiaan Peter Maria Reutelingsperger | A method for detecting and/or optionally quantifying and/or separating apoptotic cells in or from a sample |
| US7645739B2 (en) | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
| US20030152513A1 (en) | 2001-09-06 | 2003-08-14 | Imetrix, Inc. | Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector |
| JP4444821B2 (ja) | 2002-06-06 | 2010-03-31 | ツェ・チェイン・ウン | 遺伝子組み換えによる新しい抗凝血性蛋白質 |
| PT1755642E (pt) | 2004-04-15 | 2010-04-20 | Athera Biotechnologies Ab | Anexina v para prevenção de aterotrombose e da ruptura de placas |
| WO2009001224A2 (en) | 2007-06-22 | 2008-12-31 | Eth Zurich | Antivirals |
| WO2009018500A1 (en) * | 2007-07-31 | 2009-02-05 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| PL2234631T3 (pl) | 2007-12-18 | 2013-03-29 | Athera Biotechnologies Ab | Związki i metody stosowane w terapii choroby naczyniowej |
| HUE044621T2 (hu) * | 2008-02-22 | 2019-11-28 | Annexin Pharmaceuticals Ab | Vegyületek és eljárások resztenózis megelõzésére vagy kezelésére |
| CA2740557C (en) | 2008-10-17 | 2020-04-14 | London Health Sciences Centre Research Inc. | Annexin and its use to treat inflammatory disorders |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
-
2009
- 2009-10-16 CA CA2740557A patent/CA2740557C/en active Active
- 2009-10-16 WO PCT/CA2009/001469 patent/WO2010043045A1/en not_active Ceased
- 2009-10-16 EP EP09820159.3A patent/EP2349321B1/en not_active Revoked
- 2009-10-16 JP JP2011531312A patent/JP5590621B2/ja active Active
- 2009-10-16 CN CN200980150927.0A patent/CN102256617B/zh active Active
- 2009-10-16 US US13/124,330 patent/US9192649B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505837A5 (enExample) | ||
| Torres-Espín et al. | Eliciting inflammation enables successful rehabilitative training in chronic spinal cord injury | |
| Kim et al. | Mechanisms of radiation-induced skin injury and implications for future clinical trials | |
| Tetè et al. | IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation | |
| Corrigan et al. | The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains | |
| JP2019526611A5 (enExample) | ||
| AR097588A2 (es) | Agentes ligantes inhibidores de la miostatina, molécula de ácido nucleico que la codifica, vector de expresión, célula huésped incapaz de regenerar una planta o un animal, método para prepararlo, composición farmacéutica que lo comprende, su uso para la manufactura de un medicamento y método para medir miostatina en una muestra | |
| JP2006516116A5 (enExample) | ||
| JP2010520304A5 (enExample) | ||
| JP2014513722A5 (enExample) | ||
| JP2002532432A5 (enExample) | ||
| Wen et al. | SDF-1α and CXCR4 as therapeutic targets in cardiovascular disease | |
| Yang et al. | Effects of metformin on lipopolysaccharide-induced depressive-like behavior in mice and its mechanisms | |
| JP2017536380A5 (enExample) | ||
| JP2008534503A5 (enExample) | ||
| Fakhoury et al. | Use of artificial cell microcapsule containing thalidomide for treating TNBS-induced Crohn's disease in mice | |
| Cheng et al. | Anti-inflammatory effect of stem cells against spinal cord injury via regulating macrophage polarization | |
| JP2018530577A (ja) | 神経変性疾患の治療のための方法および組成物 | |
| US10639296B2 (en) | Methods to mitigate injury from radiation exposure | |
| JP2009538935A5 (enExample) | ||
| CN102552280A (zh) | 甘草酸或盐及其衍生物的制药用途 | |
| CN110225922B (zh) | 用于促进血管生成的剂及其方法和用途 | |
| CN105854018A (zh) | Wnt抑制剂在制备治疗造血再生障碍性疾病药物中的应用 | |
| CN105030822B (zh) | 有机无机杂化多阴金属氧酸盐化合物的用途 | |
| WO2016066068A1 (zh) | 金属硫蛋白复合制剂作为制备穴位介入治疗脑中风后遗症药物的应用 |